AliveGen

Executive Summary

AliveGen USA, Inc. is a privately held, clinical-stage biopharmaceutical company dedicated to discovering and developing novel biotherapeutics for diseases with high unmet medical need, including muscle wasting, bone loss, obesity, and cardiometabolic diseases. Founded in 2018 and headquartered in Thousand Oaks, California, the company leverages its proprietary platform to advance first-in-class and best-in-class therapies. Currently in Phase 1 development, AliveGen's lead candidate targets muscle wasting disorders, a significant area of unmet need with limited therapeutic options. The company's pipeline also includes programs for osteosarcopenia and metabolic diseases, positioning it to address large and growing markets driven by aging populations and rising obesity rates. With a strong scientific foundation and a clear focus on high-value indications, AliveGen represents an emerging player in the biotherapeutics space, though it remains early-stage with no approved products or disclosed partnerships.

Upcoming Catalysts (preview)

• Q4 2026Phase 1 data readout for lead muscle wasting candidate60% success
• Q2 2027IND filing for bone loss program50% success
• Q3 2026Series B financing round closure70% success